Procainamide

Evidence Level: L5 Predicted Indications: 10

Table of Contents

  1. Procainamide
    1. Pharmacist Assessment Report
    2. Procainamide: Tourette syndrome
    3. One-Sentence Summary
    4. Quick Overview
    5. Why is This Prediction Reasonable?
    6. Clinical Trial Evidence
    7. Literature Evidence
    8. Canada Market Information
    9. Safety Considerations
    10. Conclusion and Next Steps
      1. Other Predicted Indications (Brief Note)
    11. Disclaimer

Pharmacist Assessment Report

Procainamide: Tourette syndrome

One-Sentence Summary

Procainamide is an injectable antiarrhythmic (a class Ia sodium channel blocker) marketed in Canada as Procainamide Hydrochloride Injection USP. The TxGNN model (deep learning) predicts it may be effective for Tourette syndrome, but this score may reflect similarities the model learned between related diseases, not biological evidence, with 0 clinical trials and 0 publications supporting it.

Quick Overview

Item Content
Original Indication Not recorded in the local data
Predicted New Indication Tourette syndrome
TxGNN Prediction Score 0.9946
Evidence Level L5
Canada Market Status Marketed (marketed DINs: 1 of 1)
Number of DINs 1 (marketed: 1)
Recommended Decision Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Procainamide is generally known as a class Ia sodium channel blocker used for heart rhythm disorders. It has no known action on the dopaminergic or cortico-striatal circuitry implicated in Tourette syndrome.

No plausible mechanistic bridge between the original use (arrhythmia) and the predicted use (a neurodevelopmental tic disorder) is evident. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence; no trials or literature support it. The prediction should be treated as a weak hypothesis only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN Product Name Dosage Form Approved Indication
02184486 PROCAINAMIDE HYDROCHLORIDE INJECTION USP Not specified Not specified

Safety Considerations

  • Contraindications suggested by the knowledge graph (derived from drug-disease links in the TxGNN knowledge graph, not from label text):
    • Cardiac: long QT syndrome (including familial), torsades de pointes, atrioventricular block, digitalis poisoning
    • Blood: agranulocytosis, neutropenia (including several congenital forms), thrombocytopenia
    • Immune: systemic lupus erythematosus (including pediatric)
    • Neuromuscular: myasthenia gravis, neuromuscular junction disease
    • Organ and metabolic: kidney disease, liver disease, gallbladder disease, potassium deficiency, hypotensive disorder
  • Drug Interactions: The interaction screen returned 100 interacting drugs. Examples of Major interactions include clarithromycin, levofloxacin, dolasetron, palonosetron, eliglustat, picosulfuric acid, sodium sulfate, and polyethylene glycol with electrolytes. Several Moderate interactions were also noted, such as famotidine, ranitidine, cimetidine, metformin, loperamide, metoclopramide, and bisacodyl.
  • Procainamide’s autoimmune signal: Literature retrieved for other predicted indications consistently describes procainamide-induced lupus, antinuclear and anti-histone antibodies, and inhibition of T-cell DNA methylation.

Please refer to the package insert for the official warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The Tourette syndrome prediction rests only on a TxGNN model (deep learning) score, which may reflect similarities the model learned between related diseases, not biological evidence. There are no trials, no literature, and no plausible mechanism. The drug also carries significant cardiac, hematological and autoimmune safety concerns.

To proceed, the following is needed:

  • Health Canada package insert warnings, contraindications, and approved indication text (a blocking gap for safety screening)
  • Mechanism of action data (for example from DrugBank) to assess any link to tic-disorder biology
  • Preclinical or mechanistic evidence supporting a role in Tourette syndrome
  • A benefit-risk assessment addressing QT prolongation, blood dyscrasias, and drug-induced lupus

Other Predicted Indications (Brief Note)

Other predictions in the data compiled for this report also have no clinical trials and no supporting evidence. All are rated Hold:

  • Hyperthyroidism (0.9944): L5. The retrieved papers address atrial fibrillation rate control and drug-induced vasculitis, not treatment of hyperthyroidism.
  • Prinzmetal angina (0.9944): L4. The papers cover arrhythmias complicating variant angina, and class Ia agents may provoke torsades de pointes.
  • Rheumatoid arthritis (0.9912): L4. The literature shows procainamide inducing autoimmunity (drug-induced lupus), which is a safety signal rather than support.
  • Methemoglobinemia, alpha type (0.9940), methemoglobinemia (0.9933), methemoglobin reductase deficiency (0.9920), nephrogenic syndrome of inappropriate antidiuresis (0.9927), trichotillomania (0.9926), and resistance to thyroid hormone (THRB mutation) (0.9922): L5, with no plausible mechanism or evidence.

    Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

This site uses Just the Docs, a documentation theme for Jekyll.